Topic

's Online and European Editor. He can be reached at jupton@mjhlifesciences.com

Articles

Cyclacel CEO Spiro Rombotis talks about the changes he has seen during his 36-year experience in pharma and biotech and how he continues to be motivated by Cyclacel’s work on solid tumors and lymphomas.

A Marathon, Not a Sprint: Spiro Rombotis, CEO, Cyclacel

Elaine Quilici is Pharmaceutical Executive's Senior Editor. Email her at equilici@mjhlifesciences.com

Moderna Chief Medical Officer Paul Burton looks to build on culture of innovation and speed to advance COVID-19 vaccine and develop new therapies based on its novel mRNA platform, spreading hope to patients around the world.

Crafting Cures

Chris Doerr, Senior Vice President, Global Generic Sourcing, AmerisourceBergen, talks about the importance of companies taking an honest view of their current-state capabilities when embarking on the digital transformation journey.





Avoiding the Shiny Penny Syndrome of Digital Transformation

Sajith Wickramasekara, co-founder and CEO of Benchling, talks about closing the gap between research and early-stage development to accelerate scientific breakthroughs in biopharma.





Q&A: Sajith Wickramasekara, Benchling

Christian Wieszner, CSL Behring UK’s new General Manager, talks about his role and his vision for the company’s UK operation going forward.

Q&A: Christian Wieszner, CSL Behring UK

Carolynn Johnson talks about changing the diversity, equity and includsion trends among the most progressive companies.

Mentoring with a Different Lens: Insights with DiversityInc CEO Carolynn Johnson

Rafael Pharmaceuticals President and CEO Sanjeev Luther shares insights about the strategy he used to shepherd the company’s main compound, devimistat, from near-failure into Phase III trials.

Q&A: Sanjeev Luther, Rafael Pharmaceuticals

Imvax CEO John Furey taps into tried-and-true powers of hope and clarity as he moves the clinical stage biotech from single program to platform company.

Leading Through Transition

Open Orphan CEO Cathal Friel talks to Pharm Exec about how the company is distinctive from traditional CROs and its role in the UK’s COVID-19 human challenge study.

Q&A: Cathal Friel, Open Orphan

aTyr Pharma’s Dr. Sanjay S. Shukla talks about how his background in biostatistics, informatics and medicine is helping him and his team of researchers and scientists develop meaningful new medicines in a novel area of immunobiology, by looking at pathways where other drugs may have failed.

Executive Profiles